Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update
In the fourth quarter of 2021, in-market purchases were in excess of 29,000 billable units, representing sequential quarterly growth of approximately 17%.
- In the fourth quarter of 2021, in-market purchases were in excess of 29,000 billable units, representing sequential quarterly growth of approximately 17%.
- In October 2021, the Company received supplemental FDA approval expanding DEXTENZAs label to include the treatment of ocular itching associated with allergic conjunctivitis.
- General and administrative expenses were $7.5 million for the fourth quarter versus $6.6 million in the comparable quarter of 2020.
- Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.